F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma(531 views) Gallicchio R, Mansueto G, Simeon V, Nardelli A, Guariglia R, Capacchione D, Soscia E, Pedicini P, Gattozzi D, Musto P, Storto G
Keywords: Dlbcl, Glycolytic Activity, Pet Ct, Quantitative Assessment, Survival, Antineoplastic Agent, Cyclophosphamide, Doxorubicin, Fluorodeoxyglucose F 18, Monoclonal Antibody, Prednisone, R-Chop Protocol, Vincristine, Adult, Cancer Staging, Diagnostic Use, Disease Free Survival, Drug Effects, Female, Follow Up, Glycolysis, Human, Lymphoma, Large B-Cell, Diffuse, Metabolism, Middle Aged, Mortality, Pathology, Positron Emission Tomography, Predictive Value, Prognosis, Tumor Volume, Very Elderly, 80 And Over, Antibodies, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Follow-Up Studies, Neoplasm Staging, Positron-Emission Tomography, Predictive Value Of Tests, Tumor Burden, Fluorodeoxyglucose F18 Diagnostic Use Metabolism, Glycolysis Drug Effects, Diffuse Diagnosis Drug Therapy Mortality Pathology, Tumor Burden Drug Effects,
Affiliations: *** IBB - CNR ***
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Centro di Riferimento Oncologico di Basilicata (CROB), Rionero in Vulture, Italy
Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Napoli, Italy
University of Texas, Southwestern, Dallas, TX, United States
References: Stein, R.S., Greer, J.P., Flexner, J.M., Hainsworth, J.D., Collins, R.D., Macon, W.R., Cousar, J.B., Large-cell lymphomas: clinical and prognostic features (1990) J Clin Oncol, 8, pp. 1370-137
Rosenwald, A., Wright, G., Chan, W.C., Lymphoma/leukemia molecular profiling project the use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma (2002) N Engl J Med, 346, pp. 1937-1947
Stein, H., Diffuse large B-cell lymphoma, not otherwise specified (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, pp. 233-237. , Swerdlow SH, ed., 4th ed. Lyon, France: World Health Organization classification of tumours IARC Press
Novelli, S., Briones, J., Sierra, J., Epidemiology of lymphoid malignancies: last decade update (2013) Springerplus, 2, p. 70
A predictive model for aggressive non-Hodgkin's lymphoma (1993) N Engl J Med, 329, pp. 987-994. , The International Non-Hodgkin's Lymphoma Prognostic Factors Project
Shipp, M.A., Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? (1994) Blood, 83, pp. 1165-1173
Sehn, L.H., Berry, B., Chhanabhai, M., The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP (2007) Blood, 109, pp. 1857-1861
Martelli, M., Ferreri, A.J., Agostinelli, C., Di, R.A., Pfreundschuh, M., Pileri, S.A., Diffuse large B-cell lymphoma (2013) Crit Rev Oncol Hematol, 87, pp. 146-171
Cox, M.C., Nofroni, I., Ruco, L., Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma (2008) Leuk Lymphoma, 49, pp. 1745-1751
Bernd, H.W., Ziepert, M., Thorns, C., German high grade non-hodgkin's lymphoma study group (DSHNHL). Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials (2009) Haematologica, 94, pp. 1569-1580
Jerusalem, G., Beguin, Y., Fassotte, M.F., Najjar, F., Paulus, P., Rigo, P., Fillet, G., Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease (2001) Haematologica, 86, pp. 266-273
Mikhaeel, N.G., Timothy, A.R., O'Doherty, M.J., Hain, S., Maisey, M.N., 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT (2000) Leuk Lymphoma, 39, pp. 543-553
Castellucci, P., Nanni, C., Farsad, M., Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation (2005) Nucl Med Commun, 26, pp. 689-694
Storto, G., Di Giorgio, E., De Renzo, A., Pizzuti, L.M., Cerciello, G., Nardelli, A., Capacchione, D., Pace, L., Assessment of metabolic activity by PET-CT with F-18-FDG in patients with T-cell lymphoma (2010) Br J Haematol, 151, pp. 195-197
Zinzani, P.L., Fanti, S., Battista, G., Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients (2004) Br J Cancer, 91, pp. 850-854
Naumann, R., Beuthien-Baumann, B., Reiss, A., Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma (2004) Br J Cancer, 90, pp. 620-625
Schöder, H., Noy, A., Gönen, M., Weng, L., Green, D., Erdi, Y.E., Larson, S.M., Yeung, H.W., Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma (2005) J Clin Oncol, 23, pp. 4643-4651
Storto, G., De Renzo, A., Pellegrino, T., Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (2010) Radiology, 254, pp. 245-252
Ansell, S.M., Armitage, J.O., Positron emission tomographic scans in lymphoma: convention and controversy (2012) Mayo Clin Proc, 87, pp. 571-580
Ngeow, J.Y., Quek, R.H., Ng, D.C., Hee, S.W., Tao, M., Lim, L.C., Tan, Y.H., Lim, S.T., High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma (2009) Ann Oncol, 20, pp. 1543-1547
Papajík, T., Mysliveček, M., Sedová, Z., Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma (2011) Eur J Haematol, 86, pp. 32-37
Chang, C.C., Cho, S.F., Chen, Y.W., Tu, H.P., Lin, C.Y., Chang, C.S., SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma (2012) Clin Nucl Med, 37, pp. 189-195
Avivi, I., Zilberlicht, A., Dann, E.J., Leiba, R., Faibish, T., Rowe, J.M., Bar-Shalom, R., Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era (2013) Am J Hematol, 88, pp. 400-405
Kim, T.M., Paeng, J.C., Chun, I.K., Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma (2013) Cancer, 119, pp. 1195-1202
Bland, J.M., Altman, D.G., Statistical methods for assessing agreement between two methods of clinical measurement (1986) Lancet, 1, pp. 307-310
Coiffier, B., Lepage, E., Briere, J., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma (2002) N Engl J Med, 346, pp. 235-242
Habermann, T.M., Weller, E.A., Morrison, V.A., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma (2006) J Clin Oncol, 24, pp. 3121-3127
Park, S., Moon, S.H., Park, L.C., The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma (2012) Am J Hematol, 87, pp. 937-940
Seam, P., Juweid, M.E., Cheson, B.D., The role of FDG-PET scans in patients with lymphoma (2007) Blood, 110, pp. 3507-3516
Juweid, M.E., Stroobants, S., Hoekstra, O.S., Imaging subcommittee of international harmonization project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma (2007) J Clin Oncol, 25, pp. 571-578
Haioun, C., Itti, E., Rahmouni, A., (18F)fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome (2005) Blood, 106, pp. 1376-1381
Paes, F.M., Kalkanis, D.G., Sideras, P.A., Serafini, A.N., FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease (2010) Radiographics, 30, pp. 269-291
Hutchings, M., Loft, A., Hansen, M., Ralfkiaer, E., Specht, L., Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake (2006) Hematol Oncol, 24, pp. 146-150
Tang, B., Malysz, J., Douglas-Nikitin, V., Zekman, R., Wong, R.H., Jaiyesimi, I., Wong, C.Y., Correlating metabolic activity with cellular proliferation in follicular lymphomas (2009) Mol Imaging Biol, 11, pp. 296-302
Watanabe, R., Tomita, N., Takeuchi, K., Sakata, S., Tateishi, U., Tanaka, M., Fujita, H., Ishigatsubo, Y., SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma (2010) Leuk Lymphoma, 51, pp. 279-283
Chihara, D., Oki, Y., Onoda, H., Taji, H., Yamamoto, K., Tamaki, T., Morishima, Y., High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma (2011) Int J Hematol, 93, pp. 502-508
Spaepen, K., Stroobants, S., Dupont, P., Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ((18F)FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is (18F)FDG-PET a valid alternative to conventional diagnostic methods? (2001) J Clin Oncol, 19, pp. 414-419
Stein, R. S., Greer, J. P., Flexner, J. M., Hainsworth, J. D., Collins, R. D., Macon, W. R., Cousar, J. B., Large-cell lymphomas: clinical and prognostic features (1990) J Clin Oncol, 8, pp. 1370-137
Shipp, M. A., Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? (1994) Blood, 83, pp. 1165-1173
Sehn, L. H., Berry, B., Chhanabhai, M., The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP (2007) Blood, 109, pp. 1857-1861
Cox, M. C., Nofroni, I., Ruco, L., Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma (2008) Leuk Lymphoma, 49, pp. 1745-1751
Bernd, H. W., Ziepert, M., Thorns, C., German high grade non-hodgkin's lymphoma study group (DSHNHL). Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials (2009) Haematologica, 94, pp. 1569-1580
Mikhaeel, N. G., Timothy, A. R., O'Doherty, M. J., Hain, S., Maisey, M. N., 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT (2000) Leuk Lymphoma, 39, pp. 543-553
Zinzani, P. L., Fanti, S., Battista, G., Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients (2004) Br J Cancer, 91, pp. 850-854
Sch der, H., Noy, A., G nen, M., Weng, L., Green, D., Erdi, Y. E., Larson, S. M., Yeung, H. W., Intensity of 18 fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma (2005) J Clin Oncol, 23, pp. 4643-4651
Ansell, S. M., Armitage, J. O., Positron emission tomographic scans in lymphoma: convention and controversy (2012) Mayo Clin Proc, 87, pp. 571-580
Ngeow, J. Y., Quek, R. H., Ng, D. C., Hee, S. W., Tao, M., Lim, L. C., Tan, Y. H., Lim, S. T., High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma (2009) Ann Oncol, 20, pp. 1543-1547
Papaj k, T., Myslive ek, M., Sedov, Z., Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma (2011) Eur J Haematol, 86, pp. 32-37
Chang, C. C., Cho, S. F., Chen, Y. W., Tu, H. P., Lin, C. Y., Chang, C. S., SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma (2012) Clin Nucl Med, 37, pp. 189-195
Kim, T. M., Paeng, J. C., Chun, I. K., Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma (2013) Cancer, 119, pp. 1195-1202
Bland, J. M., Altman, D. G., Statistical methods for assessing agreement between two methods of clinical measurement (1986) Lancet, 1, pp. 307-310
Habermann, T. M., Weller, E. A., Morrison, V. A., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma (2006) J Clin Oncol, 24, pp. 3121-3127
Park, S., Moon, S. H., Park, L. C., The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma (2012) Am J Hematol, 87, pp. 937-940
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Imaging subcommittee of international harmonization project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma (2007) J Clin Oncol, 25, pp. 571-578
Paes, F. M., Kalkanis, D. G., Sideras, P. A., Serafini, A. N., FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease (2010) Radiographics, 30, pp. 269-291
F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(284 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote